`
`IN AND FOR THE DISTRICT OF DELAWARE
`
`ASTRAZENECA AB,
`
`Civil Action
`
`No. 14—664~GMS
`
`Civil Action
`
`No.
`
`14—666—GMS
`
`Civil Action
`
`_
`
`No.
`
`14—667—GMS
`
`~4sa~e\/sayasagagae
`
`) ) ) ) ) ) )
`
`)
`
`) )
`
`\z\/\.4\/\.a\/sax/sax;
`
`Plaintiff,
`
`V.
`
`AUROBINDO PHARMA LTD. AND
`
`AUROBINDO PHARMA U.S.A.,
`
`INC.,
`
`Defendants.
`
`ASTRAZENECA AB,
`
`Plaintiff,
`
`V.
`
`INC. ,
`WATSON LABORATORIES,
`ACTAVIS,
`INC. , and ACTAVIS LLC,
`
`Defendants.
`
`ASTRAZENECA AB,
`
`Plaintiff,
`
`V.
`
`WOCKHARDT BIO AG and
`
`WOCKHARDT USA LLC,
`
`Defendants.
`
`._
`
`_
`
`Wilmington, Delaware
`Wednesday, September 21, 2016
`9:00 a.m.
`
`Day 3 of Bench Trial
`
`BEFORE:
`
`HONORABLE GREGORY M. SLEET, U.S.D.C.J.
`
`CAPTION CONTINUES ON FOLLOWING PAGE
`
`Page 1 of 6
`
`AstraZeneca Exhibit 2218
`Mylan v. AstraZeneca
`IPR2015-01340
`
`
`
`406
`
`IN THE UNITED STATES DISTRICT COURT
`
`IN AND FOR THE DISTRICT OF DELAWARE
`
`ASTRAZENECA AB,
`
`Civil Action
`
`Plaintiff,
`
`V.
`
`SUN PHARMA GLOBAL FZE and SUN
`
`PHARMACEUTICAL INDUSTRIES LTD.,
`
`Defendants.
`
`ASTRAZENECA AB,
`
`Plaintiff,
`
`V.
`
`MYLAN PHARMACEUTICALS,
`
`INC.
`
`I
`
`Defendant.
`
`ASTRAZENECA AB,
`
`Plaintiff,
`
`V.
`
`AMNEAL PHARMACEUTICALS LLC,
`
`Defendant.
`
`
`
`sJ\.a~a;\/xaxas/xaxzx/\./\./\/xysaexesr
`
`s/~.z\/\a\¢\.r\.¢\a\/
`
`No. 14-694-GMS
`
`Civil Action
`
`No. 14-696-GMS
`
`Civil Action
`
`No. 14-697-GMS
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 2 of 6
`
`Page 2 of 6
`
`
`
`APPEARANCES:
`
`407
`
`MICHAEL P. KELLY, ESQ., and
`DANIEL M. SILVER, ESQ.
`
`McCarter & English, LLP
`—and—
`
`CHARLES E. LIPSEY, ESQ.,
`ROBERT F. SHAFFER, ESQ.,
`
`DAVID M. WEINGARTEN, Ph.D., ESQ., and
`NICOLE A CONLON, Ph.D., ESQ.
`
`Finnegan, Henderson, Farabow,
`Garrett & Dunner, L.L.P.
`
`(Washington, D.C.)
`
`Counsel for Astrazeneca AB
`
`KENNETH LAURENCE DORSNEY, ESQ.
`Morris James LLP
`—and—
`
`SAILESH K. PATEL, ESQ., and
`GEORGE YU, ESQ.
`Schiff Hardin LLP
`
`(New York, NY)
`
`Counsel for Aurobindo
`
`DOMINICK T. GATTUSO, ESQ.
`Proctor Heyman LLP
`—and-
`
`RALPH J. GABRIC, ESQ.,
`MARK H. REMUS, ESQ.,
`LAURA A. LYDIGSEN, ESQ., and
`JOSHUA JAMS, ESQ.
`Brinks Gilson & Lione
`
`(Chicago,
`
`IL)
`
`Counsel for Watson
`Laboratories and Actavis
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 3 of 6
`
`Page 3 of 6
`
`
`
`APPEARANCES CONTINUED:
`
`408
`
`DAVID BILSON, ESQ.
`
`Phillips, Goldman, McLaughlin & Hall, P.A.
`- and:
`MAUREEN L. RURKA, ESQ., and
`CHRISTOPHER P. WILSON, ESQ.
`Winston & Strawn LLP
`
`(Chicago,
`
`IL)
`
`Counsel for Sun Pharma Global
`FZE and Sun Pharmaceutical
`and Amneal
`
`DAVID E. MOORE, ESQ.
`Potter Anderson & Corroon LLP
`—and—
`
`DOUGLAS H. CARSTEN, ESQ.,
`ELLIE F. STEINER, ESQ., and
`NELLIE AMJADA, ESQ.
`Wilson Sonsini Goodrich & Rosati
`
`(San Diego, CA)
`
`Counsel for Mylan
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`L7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 4 of 6
`
`Page 4 of 6
`
`
`
`560
`
`M.
`
`JAM$5
`
`Thank you, your honor.
`
`Joshua James
`
`representing Actavis on behalf of all defendants.
`
`I introduce the deposition testimony and all
`
`relevant exhibits for Cheryl Fassak,
`
`lead for AstraZeneca's
`
`portfolio marketing team in the diabetes franchise.
`
`Both defendants and plaintiffs have identified
`
`testimony, eight minutes on behalf of the defendants,
`
`two
`
`minutes on behalf of plaintiffs.
`
`THE COURT: Great.
`
`(The videotaped deposition of Cheryl Fassak was
`
`played as follows.)
`
`"Question: Please state your name for the
`
`record.
`
`"Answer: Cheryl Fassak.
`
`
`
`
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 5 of 6
`
`Page 5 of 6
`
`
`
`Fassak — depo.
`
`567
`
`"Question: Did Caremark inform Astrazeneca
`
`or BMS why it went to a not covered tier on its formulary?
`
`"Answer:
`
`So, specifically —— so they informed
`
`us of the decision.
`
`They informed us that they —— they were
`
`evaluating rebates and that they had gone with another
`
`option with a higher rebate.
`
`"Question:
`
`Do you know if that other option was
`
`Januvia?
`
`"Answer:
`
`I'm not sure.
`
`"Question:
`
`Is that what your suspicion is?
`
`"Answer: Yes.
`
`(End of videotaped deposition.)
`
`
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 6 of 6
`
`Page 6 of 6